This summary contains the following key information: Curcumin (diarylheptanoid) is one member of a group of natural compounds called curcuminoids, derived from the rhizome of Curcuma longa, an East Indian plant, contained in an extract commonly called turmeric. Turmeric has a long history of therapeutic application in traditional Asian medicine. Extensive research over the past two decades suggests that curcuminoids, the active ingredient in turmeric (C. longa), interfere with multiple cell sign...
Curcumin has an efficacy in improving overall remission and decreasing NF-κB, VEGF, TNF-α, and IL-6 levels in myeloma patients.
The mammalian target of rapamycin (mTOR) gene serves a crucial role in the carcinogenesis of multiple myeloma. The curcumin-induced epigenetic regulation of mTOR, including promoter DNA...
Pts (#), Dosage; duration, Outcome [reference] ; 15, 0.036–0.18 g/day; 4 months, Reduced glutathione S-transferase activity ( 13 ) ; 15, 0.45–3.6 g/day; 4 months, Reduced PGE 2 production ( 14 ) ; 12, 0.45–3.6 g/day; 7 days, Reduced the levels of M 1 G ( 15 ) ; 5, 1.44 g/day; 6 months a, Reduced the number and size of polyps without any appreciable toxicity ( 16 ) ; 44, 2 and 4 g/day; 1 month, Reduced ACF formation in smokers ( 17 ) ; 126, 1.08 g/day; 10–30 days, Improved body weight, reduced serum TNF-α, and induced p53 expression ( 18 ) ; 20, 1.5 g/day; 6 weeks a, Reduced the lipid peroxidation and increased GSH content in patients( 19 ) ; 25, 8 g/day, Well-tolerated, limited absorption, and showed activity in some patients ( 12 ) ; 17, 8 g/day; 4 weeks a, Not feasible for combination therapy ( 20 ) ; 21, 8 g/day a, Safe and well-tolerated in patients ( 11 ) ; 14, 6 g/day; 7 day, every 3 weeks a, Safe, well-tolerated, and efficacious ( 21 ) ; 85, 0.1 g/day; 6 months a, Reduced the serum PSA content in combination with isoflavones( 22 ) ; 26, 4 g/day; 6 months, Decreased paraprotein load and urinary N-telopeptide of type I collagen ( 23 ) ; 29, 2–12 g/day; 12 weeks a, Safe, bioavailable, and efficacious against multiple myeloma ( 24 ) ; 16, 1.5 g/day; 30 days c, Reduced the urinary excretion of mutagens in smokers ( 25 ) ; 62, Ointment, Produced remarkable symptomatic relief in patients with external cancerous lesions ( 26 ) ; 58, 3.6 g/day, 3 months c, Reduced the number of micronuclei in mucosal cells and in circulating lymphocytes ( 27 ) ; 25, 8 g/day, 3 months, Improved the precancerous lesions ( 28 ) ; 100, 2 g/day; 7 weeks a, Well tolerated, but not efficacious ( 29 ) ; 75, 1 g/day, 7 day, Increased vitamins C and E levels, decreased MDA and 8-OHdG contents in the serum and saliva( 30 ) ; 39, 2 tablets, Decreased IKKβ kinase activity and IL-8 levels in the saliva ( 31 ) ; 5, 1.08 g/day, 1 month + 1.44 g/day, 2 months, Significant reductions in CDAI and inflammatory indices in patients ( 32 ) ; 5, 1.1 g/day for 1 month + 1.65 g/day for 1 month, Significant reduction in symptoms as well as inflammatory indices in patients ( 32 ) ; 89, 2 g/day; 6 months a, Prevented relapse of disease ( 33 ) ; 1, 0.5 g/day; 2–10 months, Associated with clinical and endoscopic remission of the disease ( 34 ) ; ex vivo, 5–20 μM; 0.5–24 h, Suppressed p38 MAPK activation, reduced IL-1β, and enhanced IL-10 levels in mucosal biopsies; suppressed MMP-3 in colonic myofibroblasts ( 35 ) ; 207, 0.072 and 0.144 g STE/day; 8 weeks c, Produced significant reduction in the prevalence of symptoms ( 36 ) ; 8, 0.5 g in food, Increased bowel motility and activated hydrogen producing bacterial flora in the colon ( 37 ) ; 18, 1.2 g/day; 2 weeks, Improved joint swelling, morning stiffness, and walking time ( 38 ) ; 45, 0.5 g/day; 8 weeks, Improved the RA symptoms in patients alone and in combination with diclofenac sodium ( 39 ) ; 50, 0.2 g/day; 3 months, Efficacious in the management andtreatment of osteoarthritis ( 40 ) ; 100, 1 g/day; 8 months, Efficacious in the long-term management of osteoarthritis ( 41 ) ; 53, 1.125 g/day; 12 weeks, Efficacy and recurrence of the disease comparable to that for corticosteroid therapy without any adverse effect ( 42 ) ; 106, 1.2 g/day; 12–18 months, Reduced the eye discomfort after a few weeks of treatment in more than 80% of patients ( 43 ) ; 46, 1.2 g/day; 6 day, Exhibited superior anti-inflammatory property compared with phenylbutazone ( 44 ) ; 60, 1 g/day; 6–12 weeks, Reduced ulcer formation after 12 weeks ( 45 ) ; 45, 3 g/day; 4 weeks, Reduced ulcer formation ( 46 ) ; 25, 0.06 g/day; 1 week a, Improved dyspeptic symptoms and reduced serologic signs of gastric inflammation ( 47 ) ; 36, 0.12 g/day; 4 weeks a, Insignificant effect on H. pylori eradication ( 48 ) ; 8, 1.125 g/day; 6–22 months, Patients recovered from the disease ( 49 ) ; 10, Twice/day; 12 weeks b, Improved the repigmentation in combination with NB-UVB ( 50 ) ; 40, 1% in gel; 4 weeks, Anti-psoriatic activity in association with suppression in PhK activity ( 51 ) ; 12, 4.5 g/day; 12 weeks, Low response rate, but well-tolerated ( 52 ) ; 1, 1.5 g/day; 4 months and 2.5 g/day; 8 months, Exhibited safety and efficacy ( 53 ) ; 33, 2–4 g/day; 24 weeks, Observations yet to be published ( 54 ) ; 34, 1–4 g/day; 6 m, Found safe and increased vitamin E level ( 55 ) ; 70, 0.045, 0.09, 0.18 g/day; 2 months, Reduced total cholesterol and LDL cholesterol, and increased HDL cholesterol and triglyceride content in patients ( 56 ) ; 10, 0.5 g/day; 7 days, Reduced serum lipid peroxides and total serum cholesterol levels, and increased HDL cholesterol ( 57 ) ; 1, 5 g/day; 3 months a, c, Reduced the fasting blood sugar from 140 to 70 mg/dl ( 58 ) ; 72, 0.6 g/d; 8 weeks, Improved endothelial function and reduced levels of oxidative stress and inflammatory biomarkers ( 59 ) ; 14, 6 g, 15–120 min, Increased postprandial serum insulin levels, insignificant effect on plasma glucose levels and the glycemic index ( 60 ) ; 240, 1.5 g/day; 9 months, Participants showed a better overall function of β cells, with higher HOMA-β and adiponectin, and lower C-peptide and HOMA-IR ( 61 ) ; 40, 1.5 g/day; 2 months c, Attenuated proteinuria, TGF-β, and IL-8 in overt type 2 diabetic nephropathy ( 62 ) ; 25, 1 g/day, 4 weeks, Improved the symptoms of disease ( 63 ) ; 24, 500 mg/day, 3 months, Decreased proteinuria, hematuria, and systolic blood pressure in patients with relapsing or refractory lupus nephritis ( 64 ) ; 43, 480–960 mg/day; 1 month a, Improved early outcomes in cadaveric renal transplantation ( 65 ) ; 40, 2.5 g/day; 8 weeks, Viral load and CD4 cells count were unaffected ( 66 ) ; 21, 0.5 g/day; 12 months, Improved the oxidative stress parameters ( 67 ) ; 76, Extract; 3 weeks c, Relieved pain due to biliary dyskinesia ( 68 ) ; 12, 0.02 g, 0.5–2 h, Reduced the gallbladder volume ( 69 ) ; 10, 3 g/day; 4 weeks a, Reduced the infections and produced beneficial immunomodulatory effects ( 70 ) ; 67, 0.1–0.25 g/day; 3 months a, Relieved the patients from disease ( 10 ) ; 528, 1 g/day; 6 months a, c, Prevented ATT-associated hepatotoxicity ( 71 ) ; 286, 1 g/day; 3 months a, Exhibited activities against As-induced genotoxicity ( 72 ) ; 7, 0.03 g, single dose, Inhibited alcohol intoxication ( 73 ) ; 143, 0.2 g/day; 2 weeks a, Enhanced the efficacy of prulifloxacin in combination with other phytochemicals ( 74 )
In this paper, we summarized the anti- MM effects of curcumin. Keywords: CRAB features; Curcumin; HRQoL; multidrug resistance; multiple myeloma; therapy.
Curcumin is an inexpensive, natural plant ingredient with protease inhibitor effects. The present study aimed to analyze the inhibitory effects of curcumin on the multiple myeloma (MM) RPMI 8226 ce...
[Curcumin Increases the Chemosensitivity of Multiple Myeloma to Bortezomib by Inhibiting the Notch1 Signaling Pathway].
Abstract Curcumin, a polyphenol extracted from Curcuma longa in 1815, has gained attention... by curcumin. Curcumin has been reported to modulate growth factors, enzymes, transcription...
There’s no proof they can stop your condition from getting worse or coming back. But there’s some early research showing they may help. Keep in mind that “too much of a good thing” can be true even with natural supplements. They can interfere with your treatment. So you should talk to your oncologist, a doctor who specializes in cancers like multiple myeloma, before taking them. They can make a recommendation based on your treatment plan and overall health. Here are some supplements that...
In combination with the FDA-approved multiple myeloma drug, carfilzomib, curcumin induced a much higher cancer cell death while normal non-cancerous cells were less affected. This suggest...